A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.

NCT01350141 Phase 2 COMPLETED Results posted

PF-04950615 is a new investigational hypercholesterolemic agent that is being tested in this study to evaluate if it can lower LDL cholesterol.

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	COMPLETED
Enrolment	46
Start date	2011-06
Completion	2012-06

Conditions

• Hypercholesterolemia
• Dyslipidemia

Interventions

• Placebo
• PF-04950615 (RN316)
• PF-04950615 (RN316)

Primary outcomes

• Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Day 85 — Baseline, Day 85
  Baseline value was calculated as the average of Day 7 and Day 1 measurements collected prior to study drug administration.

Countries

United States, Canada